StreetInsider.com News Articles

BTIG Reiterates Buy Rating on MDxHealth SA (MDXH): "attractive small-cap growth and value stock"

Wed, 04 Mar 2026 16:31:45 -0500

BTIG analyst Mark Massaro reiterated a Buy rating and $7.00 price target on MDxHealth SA (NASDAQ: MDXH)

The analyst commented, "MDx Health wrapped up a successful 2025 where they drove +20% Y/Y revenue growth on a +38% Y/Y growth in volumes. We continue to be positive on its acquisition of the ExoDx test out of Bio-Techne (TECH, Not Rated) which we view as a test addition and upgrade to its diversified prostate portfolio. Management indicated that they successfully transitioned all of its Select customers over to its ExoDx test, which we view as a positive. We think cross-training of the reps

Form 6-K MDxHealth SA For: Feb 26

Thu, 26 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260226/26070662.html

Form 6-K MDxHealth SA For: Feb 26

Thu, 26 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260226/26070662.html

MDxHealth SA (MDXH) Misses Q4 EPS by 4c, maintains guidance

Thu, 26 Feb 2026 16:02:56 -0500

MDxHealth SA (NASDAQ: MDXH) reported Q4 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $30.29 million.

GUIDANCE:

MDxHealth SA sees FY2026 revenue of $137-140 million, versus the consensus of $135.7 million.

For earnings history and earnings-related data on MDxHealth SA (MDXH) click here.

MDxHealth SA (MDXH) Misses Q4 EPS by 4c, maintains guidance

Thu, 26 Feb 2026 16:02:56 -0500

GUIDANCE:

MDxHealth SA sees FY2026 revenue of $137-140 million, versus the consensus of $135.7 million.

For earnings history and earnings-related data on MDxHealth SA (MDXH) click here.

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Thu, 26 Feb 2026 16:00:00 -0500

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter revenue growth of 19% to $29.5 million
2025 revenue growth of 20% to $107.9 million
Conference call with Q&A today at 4:30 PM EST / 22:30 CET

IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025.

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20%

Form EFFECT MDxHealth SA

Wed, 18 Feb 2026 06:10:00 -0500
si-local-file:///var/storage/secattach/20260218/26017264.html

Form EFFECT MDxHealth SA

Wed, 18 Feb 2026 06:10:00 -0500
si-local-file:///var/storage/secattach/20260218/26017264.html

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Thu, 12 Feb 2026 17:00:00 -0500

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.